Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Clinical trial NCT02748564 · TERMINATED

Trial details

NCT number: NCT02748564
Sponsor: Rutgers, The State University of New Jersey
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Melanoma Stage III Mucosal Melanoma of the Head and Neck Stage IIIA Skin Melanoma Stage IIIB Skin Melanoma Stage IIIC Skin Melanoma Stage IV Skin Melanoma Stage IVA Mucosal Melanoma of the Head and Neck Stage IVB Mucosal Melanoma of the Head and Neck Stage IVC Mucosal Melanoma of the Head and Neck

Start date: 2017-03-21
Primary completion: 2018-10-18
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.